Altering Neuronal Activity: Research and Discovery Methods- 24

Course Curriculum & Instructional Objectives

Cellular Neurobiology (BMS 325), instructed by Brent Myers, PhD, covers experimental and discovery-based methodologies for altering neuronal activity. This material forms part of Module 10: Altering Neuronal Activity, following clinical interventions (Lecture 23 on Monday, October 26) with experimental discovery approaches (Lecture 24 on Wednesday, October 28). The subsequent session focuses on cellular modulation and problem-solving applications (Lecture 25 on Friday, October 30). An Exam 4 Question and Answer review session is scheduled for 5:00 pm in room W205, preceding Exam 4 on Monday, November 2, which comprehensively evaluates Lectures 20 through 25.

The pedagogical objectives for investigating neural alterations require mastering four core competencies: first, describing the operational benefits and methodological limitations inherent to experimental lesion approaches; second, discerning the cellular and network consequences elicited by pharmacological manipulations; third, identifying the enzymatic mechanism and genetic utility of Cre recombinase; and fourth, recognizing modern targeted genetic strategies—specifically viral transduction, chemogenetics, and optogenetics—used to modulate discrete neuronal subpopulations.

Experimental Lesion Approaches in Neuroscience

Causal understanding of brain function originally developed from serendipitous human neuropathology, including the classic clinical observations of Phineas Gage following traumatic frontal lobe injury and patient H.M. following bilateral surgical resection of the medial temporal lobes. While these historical cases demonstrated that discrete anatomical structures correlate with complex behavioral and cognitive faculties, human lesions lack experimental control, anatomical precision, and reproducible boundaries. Consequently, experimental animal models employ deliberate lesion paradigms to ablate targeted neural substrates and observe subsequent behavioral and physiological deficits.

Early experimental paradigms relied on mechanical lesions, such as surgical tissue excision, suction aspiration, or micro-knife cuts designed to transect specific fiber tracts. Modern physical ablation commonly employs radiofrequency lesions, wherein a specialized stereotaxically guided electrode delivers high-frequency alternating electrical current to the target coordinate. The resulting localized hyperthermia causes thermal coagulation necrosis, destroying all biological tissue within the sphere of current dissipation, including neuronal perikarya, glia, and traversing axonal fibers.

As characterized by Kim et al. (2017, Experimental Brain Research), radiofrequency lesions placed near the third ventricle ($3V$), fasciculus retroflexus ($fr$), posterior thalamic nuclear group ($Po$), and parafascicular nucleus ($PFN$) demonstrate effective destruction of localized tissue. However, mechanical and radiofrequency lesions suffer from a major limitation: the destruction of "fibers of passage." Because axonal tracts traveling from distant structures course through adjacent neuropil, non-specific physical ablation severs these traversing pathways, causing confounding off-target behavioral phenotypes that cannot be uniquely attributed to the loss of local cell bodies.

To overcome the non-specific devastation of fibers of passage, chemical lesion techniques utilize microinjections of selective neurotoxins or excitotoxins, such as ibotenic acid, kainic acid, or NMDA. Excitotoxins selectively bind glutamate receptors situated on post-synaptic dendritic and somatic membranes, precipitating uncontrolled intracellular calcium ($Ca^{2+}$) influx, mitochondrial failure, and enzymatic autodigestion that culminates in apoptotic or necrotic cell death. Because axon cylinders traversing the region do not express post-synaptic somatodendritic glutamate receptor complexes, passing axons remain structurally and functionally intact. Histological verification, demonstrated by Choi et al. (2007, Journal of Neuroscience) in the dorsomedial and fusiform subnuclei of the bed nucleus of the stria terminalis ($BSTdm/fu$) adjacent to the anterior commissure ($ac$), utilizes neuronal nuclei ($NeuN$) immunoreactivity to label surviving neuronal soma alongside general $Nissl$ staining, which labels rough endoplasmic reticulum and RNA across all cellular elements including reactive glia.

Pharmacological Modulation of Regional Activity

While chemical lesions provide cellular selectivity over physical trauma, permanent structural ablation induces compensatory neuroplastic reorganization that can mask original physiological functions. Pharmacological modulation resolves this limitation by delivering acute, reversible alterations in neuronal excitability via stereotaxic cannula microinjections of targeted receptor agonists or antagonists into discrete anatomical coordinates.

Reversible regional inhibition is commonly achieved by microinjecting muscimol ($MUS$), a selective agonist of ionotropic $GABA_A$ receptors. Binding of muscimol induces a conformational shift that opens the receptor's intrinsic pore, allowing inward chloride ($Cl^-$) flux down its electrochemical gradient. This hyperpolarizes the membrane potential below action potential threshold and drastically decreases input resistance through shunting inhibition. Electrophysiological investigations by Constantin et al. (2013, Journal of Neuroscience) reveal that bath application of $20\,\mu M$ muscimol abolishes spontaneous action potential discharge in recorded neurons (measured across a $200\,pA$ vertical scale and $30\,s$ horizontal timecourse), with neuronal firing resuming following compound washout.

Conversely, reversible local excitation can be provoked by microinjecting $GABA_A$ receptor antagonists, most notably bicuculline methiodide ($BMI$). By competitive displacement of endogenous gamma-aminobutyric acid ($\text{GABA}$), bicuculline disinhibits post-synaptic target cells, shifting the balance of local synaptic inputs toward net excitation. Jones et al. (2011, Physiology and Behavior) demonstrated that microinfusion of $BMI$ into the medial prefrontal cortex induces intense focal cellular activation across the anterior cingulate cortex ($AC$), prelimbic cortex ($PL$), and infralimbic cortex ($IL$), as mapped by immunodetection of the immediate early gene protein product $c\text{-}Fos$, a transcriptional proxy for sustained neuronal depolarization.

A critical caveat of pharmacological intervention is that local microcircuitry influences net physiological outcomes. In heterogeneously wired microcircuits containing recurrent collateral networks or feedforward interneurons, applying an inhibitory agonist like muscimol to a dense population of local inhibitory interneurons can relieve inhibition onto downstream projection neurons. This disinhibition produces paradoxical activation rather than silencing. Similarly, pharmacological receptor antagonists can disrupt delicate homeostatic feedback loops, underscoring that global regional manipulation fails to isolate specific functional pathways.

Cell-Type Specific Approaches & Cre-lox Recombination

Resolving the mechanisms of brain function requires isolating distinct cell types within complex microcircuits. In the cerebral cortex, excitatory pyramidal projection neurons operate alongside interneuron subtypes, including parvalbumin-positive ($PV$) fast-spiking basket cells, somatostatin-positive ($SOM$) Martinotti cells, and vasoactive intestinal peptide-positive ($VIP$) interneurons. These subclasses process distinct thalamocortical ($TC$) inputs and exert differential control over local dendritic and somatic processing (Blackwell and Geffen 2017, Nature Communications).

Dissecting these intermingled networks relies on site-specific genetic engineering, centered on the $Cre\text{-}loxP$ bacteriophage P1 recombination system (Harno et al. 2013, Cell Metabolism). The enzyme Cre recombinase recognizes specific $34\,\text{base pair (bp)}$ DNA recognition sequences termed $loxP$ sites. When two $loxP$ recognition motifs are positioned in identical orientation flanking a critical exon (a "floxed" gene segment), Cre catalyzes reciprocal conservative recombination that excises the intervening DNA sequence as a circular loop, permanently inactivating the target gene within the host cell chromosome.

Conditional knockout ($cKO$) models are generated by breeding a transgenic driver line—wherein Cre recombinase is driven by a cell-type specific promoter—with a transgenic line carrying the floxed target gene. In non-target tissues lacking promoter activity, Cre is not expressed, leaving the floxed gene intact. In designated target cells, promoter activation drives Cre translation, excising the flanked gene.

Bartholome et al. (2025, Journal of Neuroscience) applied this conditional logic to probe synaptic vesicle glycoprotein 2A ($SV2A$) inside parvalbumin interneurons ($PV:SV2A\text{-cKO}$). In wild-type ($WT$) controls, fluorescent hybridization and immunochemistry reveal robust $SV2A$ exon 3 colocalization with $PV$ interneurons stained with 4',6-diamidino-2-phenylindole ($DAPI$). In $PV:SV2A\text{-cKO}$ experimental animals, $SV2A$ exon 3 transcripts are excised in $PV\text{-positive}$ cells while expression remains intact in adjacent non-parvalbumin neurons.

Beyond gene deletion, the $Cre\text{-}loxP$ system drives conditional knock-in expression of functional actuators or fluorescent reporters (e.g., green fluorescent protein, $GFP$, or $mCherry$). In these paradigms, a strong promoter precedes a transcriptional termination sequence flanked by $loxP$ sites (a "loxP-STOP-loxP" or $LSL$ cassette) positioned immediately upstream of the reporter sequence. In the absence of Cre, the stop cassette blocks transcription. Once Cre is introduced, it excises the stop sequence, enabling stable, cell-specific transgene expression for anatomical tracing or patch-clamp electrophysiology (Pati et al. 2020, Journal of Neuroendocrinology).

Viral Vector Gene Delivery Systems

While germline transgenesis provides reliable cellular targeting, generating and crossing mutant lines requires substantial time and resources. Recombinant viral vectors, particularly adeno-associated virus ($AAV$), provide an alternative method for delivering genetic payloads directly to localized neuroanatomical sites in wild-type or transgenic adult animals.

Recombinant $AAV$ genomes are engineered between two flanking $145\,\text{bp}$ inverted terminal repeats ($ITRs$), which represent the only viral sequences retained for genome replication and packaging. The internal cassette integrates an appropriate promoter, recombinant recombinase target sites ($loxP$), the transgene open reading frame, a woodchuck hepatitis virus post-transcriptional regulatory element ($WPRE$) to enhance mRNA stability and translation efficiency, and a polyadenylation ($pA$) sequence. The physical packaging capacity of standard $AAV$ capsids imposes an upper limit of approximately $\sim 4.4\,\text{kb}$ to $4.7\,\text{kb}$ between $ITRs$, restricting the size of incorporated promoters and transgenes.

Viral vectors target specific cell types through two primary strategies: direct promoter selection or intersectional recombinase-dependent configurations. Direct promoter selection involves packaging compact, cell-type specific promoters into the $AAV$ genome. For example, Wood et al. (2019, Brain Structure and Function) utilized the calcium/calmodulin-dependent protein kinase II alpha ($CaMKII\alpha$) promoter to drive yellow fluorescent protein ($YFP$) expression exclusively within glutamatergic excitatory principal neurons, showing exclusion from interneurons labeled with glutamate decarboxylase 67 ($GAD67$).

Intersectional targeting combines transgenic Cre mouse lines with Cre-dependent double-floxed inverted open reading frame ($DIO$ or $FLEX$) viral vectors. In a $DIO$ system, the transgene is inserted in the inactive antisense (inverted) orientation flanked by two alternating pairs of incompatible $lox$ variants (e.g., $loxP$ and $lox2722$). When the virus is stereotaxically infused into a brain region expressing Cre recombinase—such as delivering an $AAV8\text{-hSyn-DIO-DREADD-mCherry}$ construct into the ventral midbrain of tyrosine hydroxylase ($TH\text{-Cre}$) transgenic mice (Runegaard et al. 2018, eNeuro)—Cre inverts the transgene into the sense orientation and excises redundant $lox$ sites. This restricts functional expression exclusively to $TH\text{-positive}$ dopaminergic neurons within the physical boundaries of the injection site.

Chemogenetics (DREADDs)

Chemogenetics allows reversible modulation of neuronal membrane potentials and intracellular signaling pathways using engineered receptor proteins and biologically inert chemical ligands. The primary chemogenetic platform employs Designer Receptors Exclusively Activated by Designer Drugs ($\text{DREADDs}$), developed via directed molecular evolution of human muscarinic acetylcholine receptors (Michaelides and Hurd 2016, Neuroscience in the 21st Century). Through targeted mutagenesis, these receptors lose affinity for their endogenous neurotransmitter, acetylcholine, while gaining high nanomolar sensitivity to an otherwise pharmacologically inert ligand, clozapine N-oxide ($CNO$).

$\text{DREADDs}$ interface directly with endogenous G-protein signaling pathways, categorized into three primary functional families:

1. Excitatory $hM3Dq$: Engineered from the human muscarinic $M_3$ receptor, this construct couples to heterotrimeric $G_q$ alpha proteins ($G_q$). Ligand binding activates phospholipase C-beta ($PLC\text{-}\beta$), which cleaves phosphatidylinositol 4,5-bisphosphate ($PIP_2$) into inositol 1,4,5-trisphosphate ($IP_3$) and diacylglycerol ($DAG$). Soluble $IP_3$ diffuses to the endoplasmic reticulum, stimulating $IP_3$ receptors to release stored calcium ($Ca^{2+}$), while membrane-bound $DAG$ stimulates downstream protein kinase C ($PKC$) and protein kinase G ($PKG$) pathways. Concurrently, the depletion of membrane $PIP_2$ promotes the closure of inhibitory $KCNQ$ ($K_v7$) potassium channels, producing membrane depolarization and sustained action potential generation.

2. Excitatory Chimeric $rM3Ds$: Developed by replacing the intracellular loops of the rat muscarinic $M_3$ receptor with domains from turkey $\beta\text{-adrenergic}$ receptors, $rM3Ds$ preferentially couples to stimulatory G-proteins ($G_s$). Receptor engagement activates adenylyl cyclase ($AC$), elevating intracellular cyclic adenosine monophosphate ($cAMP$) levels and activating protein kinase A ($PKA$), enhancing intrinsic neuronal excitability.

3. Inhibitory $hM4Di$: Engineered from the human muscarinic $M_4$ receptor, this actuator couples to inhibitory G-proteins ($G_i$). Activation of $G_i$ suppresses adenylyl cyclase activity, reducing $cAMP$ production. Simultaneously, liberated G-protein beta-gamma ($G_{\beta\gamma}$) subunits bind and activate G-protein-coupled inwardly rectifying potassium channels ($GIRK$). The resulting outward efflux of potassium ions ($K^+$) hyperpolarizes the neuronal membrane potential, suppressing action potential generation and providing sustained, reversible inhibition over behavioral timescales.

Optogenetics

Optogenetics integrates optical engineering with molecular genetics to manipulate transmembrane potential at millisecond temporal resolution. By packaging genes encoding light-sensitive microbial opsins into Cre-dependent viral vectors or transgenic organisms, researchers can activate or inhibit designated neuronal populations using specific wavelengths of light.

The two foundational optogenetic tools derive from distinct microbial origins:

1. Channelrhodopsin-2 ($ChR2$): Originally isolated from the unicellular green alga Chlamydomonas reinhardtii, $ChR2$ is a light-gated non-selective cation channel. Upon absorption of blue light (activation peak $\sim 470\,\text{nm}$), the retinal chromophore isomerizes, opening the central pore to permit an inward influx of sodium ($Na^+$) and calcium ($Ca^{2+}$) down their electrochemical gradients (balanced by modest potassium, $K^+$, efflux). The net inward positive current depolarizes the cell membrane above threshold. Delivering pulsed blue light entrains high-frequency action potential trains with millisecond temporal fidelity, while sustained light illumination drives initial rapid firing followed by depolarization block.

2. Halorhodopsin ($NpHR$ / eNpHR3.0): Cloned from the halophilic archaeon Natronomonas pharaonis, $NpHR$ functions as a light-driven inward chloride pump. Exposure to yellow or amber light (activation peak $\sim 589\,\text{nm}$) drives the stoichiometric translocation of chloride ions ($Cl^-$) across the lipid bilayer into the cytosol. This active negative charge influx hyperpolarizes the neuronal membrane, rapidly and reversibly silencing action potentials during light delivery, with baseline firing resuming immediately upon shutter closure.

As described by Shirai and Hayashi-Takagi (2017, Psychiatry and Clinical Neurosciences), optogenetics provides substantial spatial and projection specificity compared to classical electrical stimulation. Electrical stimulation non-specifically depolarizes all biological elements within the conductive field, activating local cell bodies, terminal fields, and passing axons indiscriminately.

In contrast, optical soma stimulation selectively depolarizes opsin-expressing cell bodies positioned beneath an implanted optical fiber. However, because action potentials initiate in the axon initial segment and propagate down all collateral branches, activating the cell body stimulates all downstream axonal targets (e.g., projections to both target nucleus $X$ and target nucleus $Y$). Optogenetics overcomes collateral activation through optical axon terminal stimulation. Because opsin proteins traffic throughout the axolemma into presynaptic boutons, positioning an optical fiber over axonal terminals within downstream target $Y$ restricts photostimulation to that specific pathway, leaving collateral projections to target $X$ quiescent.

Questions & Review Checks

Question 1: The histological brain slice shown above comes from an experiment designed to inactivate regional neurons using the $GABA_A$ receptor agonist muscimol. Based on the labeling of activated cells (indicated by dense black chromogenic dots representing $c\text{-}Fos$ immunoreactivity) comparing the left hemisphere (saline vehicle microinjection) against the right hemisphere (muscimol infusion), did muscimol successfully suppress neural activity?

Answer: True. The saline vehicle-treated hemisphere (left) exhibits basal patterns of active cellular transcription, marked by abundant black punctate $c\text{-}Fos$ nuclei. In contrast, the contralateral hemisphere infused with muscimol (right) shows a near-complete loss of $c\text{-}Fos$ labeling, confirming effective, localized suppression of neuronal firing.

Question 2: Which of the following genetic methods can be utilized to study cell-type specific neuronal function? A. Cre-dependent recombination B. Viral vectors C. Chemogenetics D. Optogenetics E. All of the above

Answer: E. All of the above. Cre-dependent recombination provides genetic gating of target genes, viral vectors deliver genetic payloads to localized coordinates, chemogenetics ($\text{DREADDs}$) provides selective biochemical receptor-driven modulation, and optogenetics delivers precise temporal and projection-specific control over neuronal firing.